China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs
A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary…